NCT00193505View on ClinicalTrials.gov

Ifosfamide/Carboplatin/Etoposide/Rituxan Followed by Zevalin in Relapsed/Refractory Intermediate Grade B-Cell Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 31, 2003

Primary Completion Date

August 31, 2005

Study Completion Date

August 31, 2005

Conditions
Non-Hodgkins Lymphoma
Interventions
DRUG

Ifosfamide

DRUG

Carboplatin

DRUG

Etoposide

DRUG

Rituximab

DRUG

90Y Zevalin

Trial Locations (1)

37023

Tennessee Oncology, PLLC, Nashville

Sponsors

Collaborators (1)

Biogen
All Listed Sponsors
collaborator

Biogen

INDUSTRY

lead

SCRI Development Innovations, LLC

OTHER